For the treatment of osteoporosis in patients at a high risk of fragility fractures who meet ALL the following criteria: 65 years of age or older; AND Has a documented bone mineral density [BMD] T-score of less than or equal to -3; AND Has a history of prior fragility fracture(s); AND
For the treatment of osteoporosis in patients at a high risk of fragility fractures who meet ALL the following criteria: - 65 years of age or older; AND - Has a documented bone mineral density [BMD] T-score of less than or equal to -3; AND - Has a history of prior fragility fracture(s); AND - Has used an anti-resorptive agent for osteoporosis which resulted in osteonecrosis of the jaw and/or an atypical femur fracture. Note: The maximum lifetime exposure to teriparatide for an individual patient is 24 months